The Effect of Vitamin E on Oral Mucositis Induced by Chemotherapy in Non-Hodgkin Lymphoma Patients Receiving Chemotherapy

Djoko Heri Hermanto,Indri Habsari,Budi Darmawan Machsoos

doi:10.21776/ub.crjim.2020.001.02.5

Djoko Heri Hermanto, Indri Habsari + Show 1 more

Open Access

https://doi.org/10.21776/ub.crjim.2020.001.02.5

Copy DOI

Abstract

Chemotherapy-induced mucositis is a side effect of chemotherapy that often occurs in patients with solid tumors and lymphoma. Oral mucositis can affect nutritional status and the risk of infection, both local and systemic. Antioxidant Vitamin E is beneficial for the prevention and therapy of both oral and gastrointestinal mucositis. Aim: To determine the effect of vitamin E therapy on the incidence of oral mucositis in non-Hodgkin lymphoma (NHL) patients receiving chemotherapy. Methods: This is a single-blind experimental study in 62 NHL patients undergoing chemotherapy who meet the inclusion criteria. Patients who met the inclusion criteria were randomly divided into 2 groups, namely 31 patients (treatment group) received vitamin E 400 mg / IU per day for 7 days and 31 patients in the placebo group. The incidence and grade of oral mucositis were observed on day 7. Statistical analysis used Chi-Square and Mann Whitney test according to the data type. Results: a total of 67% NHL patients were male, most of whom were over 46 years of age and as many as 50% of patients used chemotherapy regimens RCHOP and CHOP. There was an incidence of oral mucositis in 35% in the placebo group and 12.9% in the treated group (p = 0.038). In the placebo group, there were 4.8% of patients with grade 2 and 3 oral mucositis, which was not found in the therapy group. Conclusion: Â treatment with vitamin E in NHL patients undergoing chemotherapy can prevent chemotherapy-induced oral mucositis and prevent its severity.

Highlights

Chemotherapy-induced mucositis is an erythematous and ulcerative lesion of the oral mucosa observed in patients with cancer treated with chemotherapy, and / or with radiation therapy
Oral mucositis developed in 22% of 1236 chemotherapy cycles, whereas GI mucositis occurred in 7% of chemotherapy cycles.[25]
It was found that the highest incidence of oral mucositis was in the age group over 46 years (61.3%), whereas proportionally the incidence of oral mucositis was higher in the 26-45 years age group than in the 45-45 years age group (46.7% vs 26.7%; p

Summary

Introduction

Chemotherapy-induced mucositis is an erythematous and ulcerative lesion of the oral mucosa observed in patients with cancer treated with chemotherapy, and / or with radiation therapy. Oral mucositis lesions are often very painful and can affect nutrition and oral hygiene and can increase the risk of developing both local and systemic infections. One study reported the incidence of oral mucositis in 303 of 599 patients (51%) with solid tumors or lymphoma who received chemotherapy.[25] Oral mucositis developed in 22% of 1236 chemotherapy cycles, whereas GI mucositis occurred in 7% of chemotherapy cycles.[25] The incidence of mucositis is influenced by the dose of chemotherapy. In hematopoietic cell transplant patients who receive high doses of chemotherapy, the incidence of mucositis is around 75-80%. In hematopoietic cell transplant patients who receive high doses of chemotherapy, the incidence of mucositis is around 75-80%. [3,4]

Objectives

Methods

Results

Conclusion